行情

SUPN

SUPN

Supernus Pharma
NASDAQ

实时行情|Nasdaq Last Sale

21.63
-0.22
-0.98%
盘后: 22.25 +0.62 +2.87% 19:50 11/12 EST
开盘
22.00
昨收
21.85
最高
22.48
最低
21.50
成交量
50.87万
成交额
--
52周最高
49.25
52周最低
19.35
市值
11.35亿
市盈率(TTM)
11.01
分时
5日
1月
3月
1年
5年

分析师评级

6位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

SUPN 新闻

  • Supernus Pharmaceuticals seeks FDA approval for ADHD drug
  • American City Business Journals.6小时前
  • Supernus to Present at Two November Healthcare Conferences
  • GlobeNewswire.8小时前
  • The Daily Biotech Pulse: Reata, Kadmon Clinical Readouts, Apyx Medical's Earnings Beat
  • Benzinga.17小时前
  • The Daily Biotech Pulse: Reata, Kadmon Clinical Readouts, Apyx Medical's Earnings Beat
  • Benzinga.17小时前

更多

所属板块

制药
+0.28%
制药与医学研究
+0.31%

热门股票

名称
价格
涨跌幅

SUPN 简况

Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy. In addition, it is developing multiple product candidates in psychiatry to address unmet medical needs and market opportunities for the treatment of impulsive aggression (IA) and for the treatment of attention deficit hyperactivity disorder (ADHD). It is developing SPN-810 (molindone hydrochloride) to treat IA in patients having ADHD. It is developing SPN-812 (viloxazine hydrochloride) as a candidate to treat patients having ADHD. The Company's neurology portfolio consists of Oxtellar XR and Trokendi XR, which are the first once-daily extended release oxcarbazepine and topiramate products, respectively, indicated for epilepsy in the United States market.
展开

Webull提供Supernus Pharmaceuticals Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。